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Abstract
Canine mammary cancer (CMC) is one of 
the most common neoplasms in intact females 
in comparison to other species. Several risk 
factors have been identified, including breed, 
genetic predisposition, age, reproductive 
history, hormonal influence, diet, and body 
condition, in addition to previous lesions 
to the mammary gland, such as mammary 
atypical hyperplasia. An understanding of the 
genetic markers for the disease and a clinical 
approach are important for establishing a 
specific therapy that can allow adequate 
patient survivorship. Overexpression of 
the HER-2 gene in canines and humans is 
associated with a poor clinical prognosis, 
mainly short survivorship, although the 
clinical relationship is not clear. The incidence 
of HER-2 in female dogs can range from 29.7% 
to 38%. However, overexpression of HER-2 is 
not necessarily associated with malignancy 
processes of the mammary tissue, although it 
participates in cellular proliferation. Finally, 
canines remain one of the most important 
models for comparative oncology with 
humans due to the great similarity in the 
spontaneous presentation and development of 
cancer, and in the high homology in the amino 
acid sequence. 
Key words: c-erbB2; diagnostic; malignant 
mammary tumour; prognosis; risk factors
Overview
The use of animal models for research 
on genetic human pathologies poses 
multiple advantages, including the 
greater size of laboratory specimens 
that facilitates their management 
(Lindblad-Toh et al., 2005; Uva et al., 
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2009), highly similar tissue development 
and architecture, and the involvement 
of similar genes. The latter enables us 
to identify and understand the clinical, 
pathological, and genetic mechanisms 
involved in the onset and development 
of cancer (expression). Studies using 
canines represent an ideal solution to 
reduce the gap between animal models 
with naturally developed diseases 
and facilitate extrapolations to human 
medicine (Rowell et al., 2011).
Mammary cancer (MC) is a highly 
complex disease due to its heterogeneous 
histopathology, biological behaviour, 
and responses to systemic interventions 
(Geleick et al., 1990; Viale, 2012). 
Furthermore, it is considered a 
worldwide public health issue (Uribe 
et al., 2013). Canine mammary cancer 
(CMC) is one of the most important 
pathologies in veterinary medicine, 
particularly in non-spayed female 
dogs (Schneider et al., 1969; Sleeckx et 
al., 2011; Beck et al., 2013). Given the 
multifactorial origin of the disease, 
prevention and treatment is complex 
(Perez-Alenza et al., 2000). CMC is 
among the main causes of mortality in 
females and this tumour pathology has 
the greatest incidence compared to other 
domestic species (Cruz, 1999). CMC 
corresponds to almost 50% of all canine 
tumours (Misdorp et al., 1999; Dhami et 
al., 2010), with an incidence estimated 
to be three times higher than in women 
(Kumaraguruparan et al., 2006; Dhami 
et al., 2010). In addition, 50% to 70% of 
canine mammary tumours (CMT) are 
considered malignant (Moe, 2001; Merlo 
et al., 2008; Salas et al., 2015). 
Canines as a model for 
naturally occurring human 
breast cancer (BC)
Canines are the most common pet 
worldwide, and it is estimated that 33% 
people over 15 years old own a dog. This 
is the most common pet in Latin America, 
Asia and Oceania, and second most 
common in Europe (GfK, 2016). This is 
due in part to ongoing social changes in 
recent years, which have led to the role of 
pets as “family members” (Sharpe, 2017), 
even influencing the owners’ finances 
(Pet Census, 2016). As a consequence, 
companion animals, particularly canines, 
are an excellent model for studying 
complex human diseases (Rowell et al., 
2011). 
At the genome level, canines share ~650 
Megabases (Mb) of ancestral sequence 
with humans (Lindblad-Toh et al., 2005; 
Pang and Argyle 2009). Also, many uni- 
or multifactorial physiological disorders 
constitute unique models for human 
diseases (Yang et al., 1999; Starkey et al., 
2005). Nearly 400 hereditary diseases in 
canines have an equivalent in humans, 
many of which have been described and 
named in the same manner (Starkey et al., 
2005). Therefore, as with murine models, 
there is increasing interest in undertaking 
comparative oncology research with 
canines (MacEwen, 1990; Pinho et al., 
2012). In canines, the evolution period 
of cancer is significantly less than in 
humans, as is the response to treatment, 
enabling preclinical studies in cancer 
development (Uva et al., 2009; Peruzzi 
et al., 2010). As such, the time period for 
evaluating cancer treatment success in 
canines is 18 months, while at least seven 
years are required in humans (Paoloni 
and Khanna, 2008). 
Canines can develop MC spontane-
ously (Macewen et al., 1982; Jaillardon et 
al., 2015) or it can be hereditary, though 
there is insufficient evidence despite the 
evident homologies with humans (Szabo 
et al., 1996; Goebel and Merner, 2017). 
The underlying genetic complexity of tu-
mour development (Aguirre-Hernández 
et al., 2009), biological behaviour, growth 
patterns, morphology, tumour progres-
sion, metastasis patterns, histological 
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types, and therapeutic response are high-
ly similar in humans (Starkey et al., 2005; 
Paoloni and Khanna, 2008; Pang and Ar-
gyle, 2009; Tamburini et al., 2009; Peruzzi 
et al., 2010; Tang et al., 2010; Gupta et al., 
2012). The epidemiological characteris-
tics are also similar between the two spe-
cies (Cassali, 2013; Vascellari et al., 2016), 
although for some cancer types, disease 
progression is more aggressive in canines 
than in humans (Meirelles, 2010; García, 
2013). Therefore, the establishment of 
oncology research protocols for the early 
detection of cancer in canines will ena-
ble its future extrapolations, followed by 
advantages for medicine and for human 
and animal survivorship.
CMC risk factors and 
pathogenesis
Different factors influence CMC 
development, including breed and 
genetic predisposition, age, reproductive 
history, hormonal activity, diet, and 
obesity (Sleeckx et al., 2011). Previous 
lesions, such as mammary atypical 
hyperplasia, can also increase the risk of 
CMC presentation (Dupont et al., 1993; 
Page et al., 2003; Ferreira et al., 2014).
Breed and genetic predisposition: 
Purebreds show a higher predisposition 
(Hemanth et al., 2015; Sahabi et al., 2015). 
French Poodle, English Springer Spaniel, 
English Spaniels, Cocker Spaniels, 
German Shepherds, Maltese, Yorkshire 
Terrier, and Dachshunds display a high 
incidence of CMC (Borge et al., 2011; 
Sleeckx et al., 2011; Caicedo et al., 2012; 
Burrai et al., 2015; Campos et al., 2015). 
Dhami et al. (2010) and Hemanth et al. 
(2015) reported other breeds that are 
highly susceptible to CMC development, 
including the Doberman, Labrador 
Retriever, Great Dane, Pomeranian, and 
Spitz (Dhami et al., 2010; Hemanth et 
al., 2015). Meanwhile, other breeds have 
been identified as low risk: Border Collie, 
Shetland Sheepdog, Bernese Mountain, 
and Saint Bernard (Borge et al., 2011). 
However, these results could be biased 
by the ownership popularity of certain 
breeds compared to others (Vidales and 
Eslava 2007; Dhami et al., 2010). Yet, there 
is a consensus regarding a higher cancer 
predisposition of small breeds compared 
to large breeds (Chang et al., 2005; Hsu et 
al., 2009; Sahabi et al., 2015).
Age: In addition to genetic 
predisposition, age also plays a 
fundamental role. CMC presentation 
is more frequent in mid to older age 
females, and an average age of six years 
has been defined as the “cancer age” 
(Perez-Alenza et al., 2000; Dhami et al., 
2010; Shinoda et al., 2014). In addition, a 
high incidence is also observed between 
9 and 10 years (Støvring et al., 1997; Hsu 
et al., 2009; Caicedo et al., 2012; Campos 
et al., 2015., Sahabi et al., 2015). However, 
there are also reports of age averages 
under 8.4 years (Chang et al., 2005), while 
authors such as Hemanth et al. (2015) 
found a higher age range of 6 to 10 years, 
with a reduction in frequency after 12 
years. 
Reproductive history: Non-spayed 
females are more susceptible to CMC than 
spayed females (Chang et al., 2005; Sleeckx 
et al., 2011; Hemanth et al., 2015; Sahabi 
et al., 2015). Females spayed before their 
first oestrous cycle have approximately 
a 0.5% risk of developing CMC, while 
ovariohysterectomy after the second 
cycle increases the risk to 8%, and to 26% 
after three cycles (Schneider et al., 1969). 
Therefore, ovarian hormone ablation 
through ovariohysterectomy performed 
during early life dramatically decreases 
dose-dependent steroid exposure, thus 
reducing the risk of early mammary 
tumour development (Sorenmo et al., 
2011). Additionally, ovariohysterectomy 
increases the survival index when 
established as a therapeutic measure for 
CMC (Hsu et al., 2009), since the survival 
index of females with CMC that undergo 
ovariohysterectomy has been found to 
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nearly double compared to non-spayed 
females (Chang et al., 2005). Nevertheless, 
there are differences among cancer types 
regarding the therapeutic impact of 
ovariohysterectomy, e.g. in females with 
complex carcinoma compared to simple 
(Chang et al., 2005).
Hormone influence: Ovarian steroid 
hormones and products with medroxy-
progesterone acetate (MPA) produce 
a proliferative effect on the mammary 
tissue, thus stimulating growth and in-
creasing the risk of mammary tumour 
development (Sleeckx et al., 2011). Ster-
oid hormones (mainly oestrogens and 
progesterone) participate in the normal 
development of the mammary tissue 
and play a key role in the early stages 
of CMC pathogenesis (Sorenmo et al., 
2011). Therefore, an ovariohysterectomy 
after the second oestrous cycle does not 
guarantee full protection from possible 
tumour development (Schneider et al., 
1969). This can be explained by the fact 
that both oestrogen receptors (ER) and 
progesterone receptors (PR) are present 
in high amounts in normal tissues and 
benign lesions, leading to accumulation 
and availability in the mammary tissue 
(Macewen et al., 1982; Rutteman et al., 
1988; Clamp et al., 2003; Rao, 2008), as 
compared to cancerous or metastatic 
tissues. Nevertheless, there is a notable 
presence of 17β-[3H] oestradiol (Mace-
wen et al., 1982). Furthermore, MPA, a 
progestin used to prevent oestrous or 
treat false pregnancy, is known to in-
crease the risk of CMC development 
(Rutteman et al., 1988; Støvring et al., 
1988). MPA induces overproduction of 
the growth hormone (GH), which induc-
es the development of dysplasia and be-
nign tumours (Perez-Alenza et al., 2000). 
The interaction of the GH in the mam-
mary tissue stimulates the insulin-like 
growth factor 1 (IGF-1).
Prolactin (PRL) is a 199 amino acid 
peptide with a molecular weight of 23 
kDa (Freeman et al., 2000), synthesized 
by the anterior pituitary gland. This 
peptide displays a luteotrophic action 
that is especially important during the 
second half of pregnancy (Verstegen-
Onclin and Verstegen, 2008; Rufo 
et al., 2016), participates in cellular 
development and differentiation of 
the canine mammary gland (Jöchle, 
1997; Rufo et al., 2016), and carries out 
lactogenic activity (Michel et al., 2012a), 
among other functions. Although the 
role of PRL in tumour development in 
the canine mammary gland is still under 
debate, several studies have proposed 
that tumour genesis in the pituitary 
gland is associated with decreased 
secretory activity (El Etreby et al., 
1980). This agrees with later studies that 
reported a reduced expression of the 
prolactin receptor (PRLR) (Michel et al., 
2012b). In addition, findings have shown 
high levels of PRL in CMC compared to 
benign lesions or hyperplasias (Queiroga 
et al., 2005). These authors indicate that 
most PRL present in cancerous tissues 
is not of pituitary origin. This has been 
demonstrated in humans (Ginsburg and 
Vonderhaar, 1995), where there might 
be an autocrine and paracrine effect 
(Ben-Jonathan et al., 2002; Clevenger et 
al., 2003).
Diet: Homemade food, such as those 
rich in fat and beef and pork, increase 
susceptibility to CMC compared to diets 
rich in poultry or balanced diets (Alenza 
et al., 2000; Sleeckx et al., 2011).
Overweight and obesity: Body fat 
ranges from 15 to 25% in healthy 
animals, while more than 30% is 
considered obesity (Burkholder et al., 
2000). However, this relationship tends 
to be narrower as age increases (German, 
2006). Body mass and overweight status 
can be assessed through morphological 
analysis with determination of body fat 
(Burkholder et al., 2000), e.g. the Canine 
Body Mass Index (IMCC) (Muller et 
al., 2008) or Escore of Body Condition 
(ECC) (Laflamme, 1997). Adipocytes are 
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the functional unit of fatty tissue (Khan 
et al., 2015). They have high metabolic 
activity and are highly sensitive to 
nervous, nutritional and hormonal 
control (Stephens, 2012) and about 
95% of the cell weight is represented 
by triglycerides (Khan et al., 2015). 
However, being overweight alters the 
release of certain substances, including 
leptin (German et al., 2010). This protein 
hormone specific to adipocytes of 167 
amino acids, has been known for its 
appetite control effects (Facey et al., 
2017) and is linked to the regulation of 
body mass (Hassink et al., 1996).
In dogs and humans, an increase in 
leptin has been found when adipose 
tissue is more abundant (Maffei et al., 
1995; Gayet et al., 2004; Kil and Swanson, 
2010), implying cell proliferation by 
stimulation of the IGF-1 or somatomedin 
and promotion of angiogenesis 
(Renehan et al., 2006). In BC, the leptin 
receptor (ObR) and Human Epidermal 
Growth Factor Receptor type 2 (HER-
2) can be co-expressed, which reduces 
the effectiveness of HER-2 treatments 
(Fiorio et al., 2008), since ObR can 
mediate HER transactivation-2 (Soma et 
al., 2008), although this is controversial 
(Santillán et al., 2012). The positive 
relationship between ObR and HER-
2 has also been observed in animals 
(rodent models) with mammary tumour 
(García-Robles et al., 2013), although 
this interaction is not yet clear (Lim et 
al., 2015).
In female dogs, obesity during the 
first year of life markedly increases the 
risk of cancer, since several carcinogenic 
events occur in the mammary gland 
during this period, although there is no 
clarity on this mechanism (Sonnenschein 
et al., 1991; Perez-Alenza et al., 2000; 
Sorenmo et al., 2011; Lim et al., 2015). 
Several findings have shown that the risk 
is similar if a female is obese at least one 
year prior to being diagnosed with CMC 
(Shofer et al., 1989). 
Clinical aspects and diagnosis 
of CMC
Clinically, tumour masses are the main 
warning of abnormality in the mammary 
glands of female dogs. The size of these 
masses can range from 0.5 cm to 21 cm 
in diameter (Chang et al., 2005; Hsu et 
al., 2009). Consequently, the clinical 
significance of canine tumour masses 
indicates that small and hard masses are 
more likely benign, while larger masses 
generally display ulceration and are 
histologically malignant (Hemanth et al., 
2015). Thus, the latter result in a more 
unfavourable prognosis (Hsu et al., 2009). 
All mammary glands can be involved 
in the development of CMC, whether 
initially one gland is involved or a 
combination of them, and these can show 
the same or different histological features 
(Perez-Alenza et al., 2000; Goebel and 
Merner, 2017). There is no tendency 
towards one side more than the other 
(Chang et al., 2005; Hsu et al., 2009; 
Hemanth et al., 2015), though findings 
have shown that the caudal mammary 
glands (glands 3, 4 and 5) are more 
affected than the thoracic pairs (1 and 2) 
(Chang et al., 2005; Hsu et al., 2009). In 
consequence, the inguinal zone is most 
affected, while the least affected is the 
caudal thoracic sector (Hemanth et al., 
2015). 
Additionally, lymphatic drainage in 
healthy females is ipsilateral (towards 
the same side) and there is no evidence 
of drainage towards the contralateral 
lymph nodes (LN) (Pereira et al., 2003; 
Pereira et al., 2008), which is one of the 
differentiating factors in neoplastic 
glands (Patsikas et al., 2006). However, 
not all CMC types behave in the same 
manner, e.g. epithelial type neoplasms, 
such as carcinomas, generate metastasis 
through the lymphatic system, while 
mesenchymal neoplasms, such as 
sarcomas, achieve metastasis through 
capillaries and veins (Sorenmo et al., 
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2011). There are correlations between 
CMC patient survival and the number of 
affected LN, where average survivorship 
decreases with increasing number of 
affected LN (Carter et al., 1989; De 
Araújo et al., 2015). Tumour size and LN 
condition are independent prognostic 
factors; however, they are additive 
(Carter et al., 1989), since a larger tumour 
diameter is related to metastasis to the 
lymph node (Chang et al., 2005). This fact 
indicates a direct relation between these 
two factors.
CMC and genetic markers
In hereditary human BC, alterations 
of the suppressor gene p53 and mutations 
in suppressor genes BRCA1 and BRCA2 
(Breast Cancer 1, 2) are mainly involved 
(Overgaard et al., 2000; Honrado et al., 
2006; Olivier et al., 2006; Pérez-Losada 
et al., 2011). In sporadic MC, there is an 
involvement of modulators of cellular 
proliferation, including alterations 
in ER, which are classified into three 
groups: classic ERα, ERβ, and the most 
recently described, GPR30 (G protein-
coupled receptor 30) (Prossnitz et al., 
2007; Hazell et al., 2009; Prossnitz and 
Maggiolini, 2009). The first two ER 
groups belong to the superfamily of 
nuclear receptors that regulate elements 
at the nuclear level through MAPK-type 
responses (Mitogen-Activated Protein 
Kinases), PI3K (Phosphoinositide (PI) 
3-Kinase), and cAMP (cyclic adenosine 
monophosphate). Alterations in these two 
receptors lead to cellular proliferation, 
growth, and survival. ER are implied 
in high resistance to treatments and 
development of metastasis, in co-
expression with the HER-2 gene (Filardo 
et al., 2006). Another group consists 
of Transforming growth factor (TGF β), 
which includes three members (TGF 
β I-III). A reduction in the expression 
of TGF β enables the development of 
MC and eventual metastasis (Landis et 
al., 2005; Dong et al., 2007). In addition, 
PGDF (Platelet-Derived Growth Factor) 
receptors include two types, PGDFR 
α and β, which are related to cellular 
proliferation and differentiation. Tumour 
invasion capacity has been correlated 
with co-expression of PGDFR α and 
HER-2 (Carvalho et al., 2005). Finally, 
the Protease-activated receptor (PAR) 
participates in the modulation of cancer 
growth (Ceballos and Hernández, 2008). 
PAR1 mediates calcium signalling, 
transcription processes, and mitogenesis 
(Coughlin, 2000). HER-2 contributes to 
PAR1 activation, therefore, providing 
high prognostic value (Ceballos and 
Hernández, 2008). 
In canines, mutations in genes 
with high or low penetrance in cancer 
considerably increase the risk of 
CMC presentation. Single Nucleotide 
Polymorphisms (SNP) in coding 
regions can lead to alterations in protein 
structure or function (Borge et al., 2011). 
Genes that show different risk levels 
have been the most studied, including 
breast cancer susceptibility genes 1 and 
2 (BRCA1, BRCA2), tumour protein p53 
(TP53), phosphatase and tensin homolog 
(PTEN), checkpoint kinase 2 (CHEK2), 
ataxia telangiectasia mutated (ATM), 
and human epidermal growth factor 
receptor-2 (HER-2) (Hsu et al., 2009; 
Borge et al., 2011).
CMC and clinical implications 
of the HER-2 gene
In women with BC, the overexpression 
of HER-2 (HER-2 positive state) is found 
between 20% and 30%, and is generally 
correlated with a high phenotypic 
aggressiveness and resistance to cytotoxic 
and endocrine therapies (González et 
al., 2007; Fehm et al., 2007; Savino et al., 
2009; Park et al., 2014). The latter leads 
to a poor clinical prognosis, mainly 
short survivorship (Slamon et al., 1987; 
Gambini et al., 2003; Ross et al., 2003), 
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and in both humans and canines, the 
prognosis is reserved for up to two years 
after surgery (Ressel et al., 2013). 
The oncogene HER-2/neu was initially 
isolated from neuroectodermal tumours 
in rats and compared to its homologues 
in humans and rabbits; therefore, neu 
corresponds to neuroblastoma (Shih 
et al., 1981). In humans, HER-2/neu 
maps to chromosome 17q 12-21.32 
(Akiyama et al., 1986; Fukushige et al., 
1986; Popescu et al., 1989; Fehm et al., 
2007; Finn et al., 2009; Krishnamurti 
and Silverman, 2014). In canines, the 
gene is located on chromosomes 9 and 
5 (Yang et al., 1999); however, it has also 
mapped to chromosome 1q13.1 through 
fluorescence in situ hybridization (FISH) 
(Murua Escobar et al., 2001). HER-2/
neu is a membrane protein of 185-kDa 
(Manguire et al., 1989), conformed 
by three domains: a transmembrane 
lipophilic domain, an extracellular 
domain (ECD) (105 -kDa), and an 
intracellular tyrosine kinase domain (Ha 
et al., 2015; Di Gioia et al., 2015). HER-2 
carries out an important role in regulating 
cellular growth and differentiation 
(Yarden, 2001). However, it has gained 
importance given its participation in the 
physiopathological progression of the 
mammary tumour and low response to 
treatments (Akiyama et al., 1986; Lüftner 
et al., 2003). 
In humans, the clinical significance 
of HER-2 is relevant, because it is 
overexpressed in early stages of cancer 
development. In consequence, it has 
become a therapeutic target (Hanna, 2001; 
Yarden, 2001; Wilson et al., 2002; Reddy 
et al., 2004; Finn et al., 2009; Krawczyk 
et al., 2009; Onitilo et al., 2009; Page et 
al., 2011; Soares et al., 2016). Yet, unlike 
the other receptors (HER-1, HER-3, and 
HER-4), HER-2 oncogenesis is attributed 
to an increase in the expression of a non-
mutated receptor. As a result, there is an 
increase in tyrosine-kinase activity, which 
induces cellular transformation (Siegel et 
al., 1994; Biscardiet et al., 2000; Yarden 
2001; Stefano et al., 2004; Moasser, 2007). 
Therefore, HER-2 is closely related with 
the rate of cancer progression (González 
et al., 2007). This is due to a deletion 
in exon 16 of the extracellular domain 
(Siegel et al., 1994) and a polymorphism in 
codon 655 (Papewalis et al., 1991). Hence, 
MC with overexpression of HER-2 highly 
correlates with metastasis in regional 
lymph nodes and, for this reason, HER-2 
is used as a prognosis marker in relation 
to other proteins p53, Ki67, ER, and PR 
(Selvarajan et al., 2004). 
There is a 29.7% incidence of HER-
2 overexpression in female canines 
diagnosed with malignant mammary 
tumour (Hsu et al., 2009). Later studies 
showed incidence rates of 28.6% (Ressel et 
al., 2013), 38% (Shinoda et al., 2014), 37.5% 
(Burrai et al., 2015) and 32.1% (Campos et 
al., 2015). However, the results regarding 
HER-2 expression levels are not yet clear 
(Hsu et al., 2009; Ressel et al., 2013). HER-
2 overexpression is seemingly not strictly 
associated with the initial stages of 
atypical cellular proliferation (Ferreira et 
al., 2014), indicating a high complexity in 
terms of establishing the most adequate 
prognosis and therapy for each type of 
CMC (Resssel et al., 2013). 
In canines, it is likely that HER-2 only 
participates in proliferation and not in 
the malignancy process of the mammary 
tissue during tumour formation (Hsu et 
al., 2009; Ressel et al., 2013). Nevertheless, 
this can vary, since there have been reports 
of CMC processes with amplification or 
overexpression of HER-2 (Rungsipipat 
et al., 1999), and of others with no 
association to HER-2 (De las Mulas et 
al., 2003). This poses a challenge for 
prognosis (Dutra et al., 2004), as findings 
are not clear regarding the effects of HER-
2 on the survivorship rate in comparison 
to other genes (Hsu et al., 2009; Shinoda 
et al., 2014). However, a HER-2 positive 
state means an unfavourable prognosis, 
both for women (Savino et al., 2009) and 
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in most canine female cases (Hsu et al., 
2009; Ressel et al., 2013).
HER-2 as a tumour marker in 
CMC
A tumour marker (TM) is a molecule 
(glycoprotein, generally) that can be 
produced by normal cells and tumour 
cells, although levels are higher in the 
presence of cancer (Hermida et al., 2016). 
In cancer, concentrations of TM can be 
produced by both normal cells and cancer 
cells, and these substances are detectable 
in biological fluids (Romero et al., 2002; 
Almeida et al., 2007). TMs may be 
tumour-specific proteins (tumour antigen 
specific), nonspecific protein tumour 
markers associated with malignant cells, 
or specific proteins overexpressed in 
malignant cells (Lindblom and Liljegren, 
2000; Romero et al., 2002). No TM is 
totally sensitive and specific, but together 
with other clinical procedures can take 
specific therapeutic decisions (Koshida 
et al., 1996; Lindblom and Liljegren, 2000; 
Hermida et al., 2016).
HER-2/neu (HER-2) is a proto-
oncogene that encodes a glycoprotein 
that stimulates cell proliferation and 
differentiation in normal epithelial cells 
(Yarden and Sliwkowski, 2001; Farzadnia 
et al., 2010). In humans, overexpression 
of the HER-2 protein has been found in 
20 to 30% of invasive breast cancer cases 
(Slamon et al., 1987; Wolff et al., 2013). The 
concentration in serum has an important 
prognostic value (Andrulis et al., 1998; 
Sjögren et al., 1998; Agrup et al., 2000) 
and it has high influence on treatment 
decisions (Leyland-Jones, 2002). 
In human breast cancer (HBC), 
HER-2 levels in blood serum have been 
studied in metastatic cancer (Jensen et 
al., 2003). Serum concentrations of 18.5% 
have been reported (Carney et al., 2003), 
and 13.4% with significant correlation 
with tumour size and clinical grade by 
immunohistochemical analysis (IHC) 
(Harris et al., 2001) and ELISA in primary 
HBC (Pallud et al., 2005). Other studies 
have not found a positive correlation 
between clinical-pathological variables 
and elevated serum levels (Kong et 
al., 2006). The cut-off value for serum 
measurements of HER-2 should be 
determined for each type of population 
(Ellis et al., 2000; Rakha et al., 2015) due 
to the little relation that there could be 
with the amplification of the gene or the 
overexpression of the protein (Kong et 
al., 2006).
The BLAST alignment of HER-2 
reveals a 92% homology in the amino 
acid sequence between humans and 
canines (Singer et al., 2012). However, the 
use of human test kits for enzyme-linked 
immunosorbent (ELISA) to measure 
concentrations of HER-2 in dogs did 
not significantly differentiate between 
healthy patients and those with cancer 
(Campos et al., 2015). However, the 
correlation of serum levels of HER-2 with 
tumour size, high histological grade, 
mitotic index and nuclear polymorphism 
indicated a poor prognosis (Dutra et al., 
2004; Hsu et al., 2009; Muhammadnejad 
et al., 2012; Kaszak et al., 2018), although 
this relationship is controversial (Kim et 
al., 2011; Ressel et al., 2013). Additionally, 
reduced expression has been reported in 
the presence of aggressive tumours such 
as ducal carcinoma in situ (DCIS) (Silva 
et al., 2014), unlike that found in feline 
mammary cancer (FMC) (Soares et al., 
2016).
Currently, it has been difficult to 
determine the similarities or differences 
in the overexpression of HER-2 between 
humans and canines. In canines, we find 
the deletion of exon 16 or the absence of 
polymorphism of codon 655, yet there 
is a polymorphism in exon 14 (Hsu et 
al., 2009). Nonetheless, it is important to 
differentiate between diagnostic methods 
with high sensitivity, in order to clearly 
establish similarities and relations in 
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this gene between humans and canines 
(Savino et al., 2009).
Conclusions
The differences between the 
overexpression of HER-2 in human 
BC and CMT are not yet clear. Despite 
recognizing the importance of HER-2, 
the clinical usefulness of its detection in 
animal medicine is still unclear, since 
the relationship between overexpression 
of HER-2 and CMC may be due to the 
interaction of several genes and not to 
the activity of the gene itself. In addition, 
care must be taken to determine HER-2, 
since it is overexpressed in other types 
of tumours, therefore it is necessary to 
supplement the clinical correlation with 
other clinical analyses. In humans, high 
levels of ECD in primary BC have a high 
diagnostic, prognostic and therapeutic 
value, while in canines, the pattern of 
presentation is not clear and survival 
findings are controversial. Given the 
high complexity involved in monitoring 
HER-2 in female dogs, it is important to 
develop studies with simple, minimally 
invasive methods that would allow for 
early detection.
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Tumor mliječne žlijezde kuja je 
jedna od najčešćih neoplazija u ženki u 
usporedbi s drugim vrstama. Ustvrđeno 
je nekoliko čimbenika rizika uključujući 
pasminu, genetsku predispoziciju, dob, 
reproduktivnu anamnezu, hormonalni 
utjecaj, hranidbu i tjelesnu kondiciju uz 
prethodne lezije mliječne žlijezde kao što 
su primjerice atipična hiperplazija mliječne 
žlijezde. U cilju uspostavljanja specifične 
terapije koja bi omogućila prihvatljivo 
vrijeme preživljavanja pacijenata važno 
je razumijevanje genetskih markera za 
spomenutu bolest kao i klinički pristup. 
Prekomjerna ekspresija HER-2 gena u kanida 
i ljudi povezana je s nepovoljnom kliničkom 
prognozom, uglavnom s kratkim vremenom 
preživljavanja, premda nije jasna njihova 
klinička povezanost. Incidencija HER-2 u 
kuja može biti u rasponu od 29,7 % do 38 %. 
Međutim, prekomjerna ekspresija HER-2 nije 
nužno povezana sa zloćudnim procesima u 
tkivu mliječne žlijezde, premda ima ulogu u 
staničnoj proliferaciji. Naposljetku, kanidi 
su i dalje najvažniji modeli za komparativnu 
onkologiju u odnosu na ljude zbog velike 
sličnosti u spontanom izgledu i razvoju 
tumora kao i u visokoj homologiji u slijedu 
aminokiselina. 
Ključne riječi: c-erbB2, dijagnostika, 
zloćudni tumor mliječne žlijezde, prognoza, 
čimbenici rizika
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